TY - JOUR
T1 - Association of Proton Pump Inhibitors With Higher Risk of Cardiovascular Disease and Heart Failure
AU - Bell, Elizabeth J.
AU - Bielinski, Suzette J.
AU - St. Sauver, Jennifer L.
AU - Chen, Lin Y.
AU - Rooney, Mary R.
AU - Larson, Nicholas B.
AU - Takahashi, Paul Y.
AU - Folsom, Aaron R.
N1 - Publisher Copyright:
© 2021 Mayo Foundation for Medical Education and Research
PY - 2021/10
Y1 - 2021/10
N2 - Objective: To examine associations of cumulative exposure to proton pump inhibitors (PPIs) with total cardiovascular disease (CVD; composed of stroke, coronary heart disease, and heart failure [HF]) and HF alone in a cohort study of White and African American participants of the Atherosclerosis Risk in Communities (ARIC) study. Methods: Use of PPIs was assessed by pill bottle inspection at visit 1 (January 1, 1987 to 1989) and up to 10 additional times before baseline (visit 5; 2011 to 2013). We calculated cumulative exposure to PPIs as days of use from visit 1 to baseline. Participants (n=4346 free of total CVD at visit 5; mean age, 75 years) were observed for incident total CVD and HF events through December 31, 2016. We used Cox regression to measure associations of PPIs with total CVD and HF. Results: After adjustment for potential confounding variables, participants with a cumulative exposure to PPIs of more than 5.1 years had a 2.02-fold higher risk of total CVD (95% CI, 1.50 to 2.72) and a 2.21-fold higher risk of HF (95% CI, 1.51 to 3.23) than nonusers. Conclusion: Long-term PPI use was associated with twice the risk of total CVD and HF compared with nonusers. Our findings are in concordance with other research and suggest another reason to be cautious of PPI overuse.
AB - Objective: To examine associations of cumulative exposure to proton pump inhibitors (PPIs) with total cardiovascular disease (CVD; composed of stroke, coronary heart disease, and heart failure [HF]) and HF alone in a cohort study of White and African American participants of the Atherosclerosis Risk in Communities (ARIC) study. Methods: Use of PPIs was assessed by pill bottle inspection at visit 1 (January 1, 1987 to 1989) and up to 10 additional times before baseline (visit 5; 2011 to 2013). We calculated cumulative exposure to PPIs as days of use from visit 1 to baseline. Participants (n=4346 free of total CVD at visit 5; mean age, 75 years) were observed for incident total CVD and HF events through December 31, 2016. We used Cox regression to measure associations of PPIs with total CVD and HF. Results: After adjustment for potential confounding variables, participants with a cumulative exposure to PPIs of more than 5.1 years had a 2.02-fold higher risk of total CVD (95% CI, 1.50 to 2.72) and a 2.21-fold higher risk of HF (95% CI, 1.51 to 3.23) than nonusers. Conclusion: Long-term PPI use was associated with twice the risk of total CVD and HF compared with nonusers. Our findings are in concordance with other research and suggest another reason to be cautious of PPI overuse.
UR - http://www.scopus.com/inward/record.url?scp=85116006608&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116006608&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2021.02.025
DO - 10.1016/j.mayocp.2021.02.025
M3 - Article
C2 - 34607633
AN - SCOPUS:85116006608
SN - 0025-6196
VL - 96
SP - 2540
EP - 2549
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 10
ER -